Q2 2021 Zoetis Inc Earnings Call
Perfect.
[music].
For your program is about to begin the journey.
The audio assistance for today's program. Please press Star zero.
John.
Welcome to the second quarter 2021 of <unk> financial results conference call and webcast for ease of lettuce.
Hosting the call today is Steve Frank Vice President of Investor Relations for the Alliance.
The presentation materials and additional financial tables are currently posted on the Investor Relations section of the wettest Dot com.
The presentation slides can be managed by you the viewer and will not be forwarded automatically.
A replay of this call will be made available approximately 2 hours. After the conclusion of the call via the island or on the Investor Relations section of the wettest Dot com.
At this time, all participants have been placed in a listen only mode and the floor will be opened for your questions. Following the presentation.
If you would like to ask a question at that time. Please press star 1 on your Touchtone.
The certain financial measures, which were not prepared in accordance with generally accepted accounting principles or us GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable us GAAP measures is included in the financial tables that accompany our earnings press release, and then the company's 8-K filing David today.
Day Thursday August 5th 2021, we also site operational results, which exclude the impact of foreign exchange with that I will turn the call over the Kristen.
And can Steve and good morning, everyone.
In your lap items are all staying housing and getting vaccinated for COVID-19.
To start the call by marketing, our new Chief Financial Officer, What me, Jeff who is joining the on the call today.
As the farmers CFO of Cat on let me as a veteran of the Biopharma industry and very familiar with many of you in the investment community Whitney do you like kind of on June 1st and it's off to of fast are learning all about the company and the animal house everything from capital of items and drive impact the pet care trends in Paris criticized the season.
I am confident that Whitney will make strong contribution to our ongoing market performance value creation and leadership and animal health.
I also wanted to take a moment to think Glenn David first partnership and all of his contributions to the whiteness of CFO over the last 5 years.
Glenn has taken on a new role overseeing our international operations and other business units, including far back by of devices and Pumpkin pet insurance.
No. He will bring his signature of leadership qualities business skills and industry now to this role and continued driving profitable growth in these areas.
Net turning to the second quarter, we achieved strong results once again with 22% operational growth in revenue and 28% operational growth and adjusted net income.
Our companion animal portfolio generated 36% operational revenue growth driven by our pet care Parasiticide key dermatology products vaccines and diagnosed.
Meanwhile, livestock product sales were up 3% operationally and remain in line with our expectations for more moderate growth. This year. The second quarter results also reflected favorable comparisons to last year's second quarter. When the uncertainty of COVID-19, and related Lockdown, where most severely felt across the animal health industry.
We are raising full year guidance for revenue and adjusted net income again this quarter to reflect our first half performance and confidence in the underlying growth drivers of our business.
We remain on track for a very strong here and continue to focus on sustaining our investment in long term growth opportunities.
With the strong cash flow and positive outlook, we are investing internally and externally and innovative new products market expansion plans and direct to consumer promotion that will support future growth.
Our team has been delivering strong growth based on internally developed companion animal parents set asides led by the Pentagon Proheart and Revolution plus franchises we.
We've redefined care for the dermatology category with our development of Apple file inside of point, and we see more growth potential coming from our monoclonal antibodies for osteoarthritis pain, new vector vaccines for poetry, and the industry first cloud day diagnostic platform with AIG capabilities.
In terms of our monoclonal antibodies for alleviation of OA pain in dogs and cats, we continue to anticipate you as the approval for Labella Edsel Elsia in 2022.
Meanwhile, initial customer response from best and pet owners in Europe has been excellent and the the.
Recently received approval of Valencia in Canada.
I always say with great price that we have the best field for us and the animal health industry, and we will continue to expand their scope effectiveness and digital tools and waved the can enhance our customer of experience and support our growth objected.
We've also seen of positive return on our investment in direct to consumer promotions for some paragraph Apple quell and disease awareness over the years and DTC remains an area of ongoing investment to support our parasiticide and dermatology portfolios.
And finally, we continue to look externally for business development opportunities that can complement our portfolio and expand our market presence of our capability yesterday, we announced plans to acquire Turok of privately held animal health company based in Australia.
Second the clothes in the first half of 2022, the acquisition will provide us with growth opportunity manufacturing capacity and increased capabilities in Australia are fifth largest market and also bring us a range of companion animal and livestock products primed for global expansion.
As I wrap up my remarks are growth story for this year remains very consistent based on the 3 recurring catalysts first or companion animal portfolio, driven by our triple combinations imperative trio and other parents satisfied our dermatology treatments apropos of inside of point, new monoclonal antibodies for pain.
And our vet, Ken diagnostic systems.
The entire portfolio is benefiting from strong take care of trends in terms of increasing clinic visit rising spend for visit and of focus on diagnostics and specialty care, especially among newer and younger generations of pet owners.
Recent estimates for market growth and companion animal products are in the high single digits and the wettest continues to expect to grow faster than the market for gaining share in the approximately 5 billion dollar global parents day decides market for pets, and we're excited by a veterinarian and pet owner responses to our new monoclonal antibodies for pain.
We also continue to see progress in the early launch index scanned images, which leads to a second catalyst for growth diagnostics, which posted 38% operational revenue growth in the second quarter as accurate the vet clinics in the U S rebounded from the year ago quarter of.
The third growth catalyst is international where we continue to generate strong operational growth driven by China, and Brazil, which grew at 30% and 40% respectively.
All of the catalyst for growth are buoyed by our priority to champion a healthier and more sustainable future commitments to our communities animals and the planet you can read more about our progress on these ESG goals and our first sustainability report, which is published in June.
In closing, we had a great second quarter, and we're focused on delivering a record setting year.
The market dynamics and animal health remains strong steady and resilience even during the challenging times based on People's Unbreakable bond with animals.
For the remainder of the year are diverse portfolio innovative pet care products strength and diagnostics and expansion in international markets will continue driving our performance now let me hand things off the whitening.
Thank you and good 1 of your game.
Before I just go for a second quarter performance I would like to take a moment to express how excited items of joined Zoetis, accompanied with an exception of opportunity for moving for a long term growth driven by the durability and resiliency of the existing portfolio. The robust part of the pipeline and the team focused on future innovation.
I'll look forward to leading an outstanding funding for organization and maintaining the financial principle investment strategies, which physician 2 orders of the world leader and animal health.
I would also like 2 weeks worth of our appreciation for the Zoetis colleagues and the the investment community for such a warm and gracious welcome.
Or of the pleasure of speaking with several of our investors since becoming CFO and I'll look forward to the connecting with maybe more in the form of weeks.
Now keeping focused the earnings.
This morning, a ripple of our commentary on our second quarter financial results.
Hidden factors for performance and and they'll be on our improved full year of 2021 guidance.
In the second quarter, we generated revenue of $1.9 billion during the 26% on the reported basis and 22% operational.
Adjusted net income of $566 million was an increase of 33% on the reported basis and 28% of operationally.
Operational revenue from 22% with 2% from price and 20% from volume.
Volume growth includes 12% from other among products.
From central new products, and 2% from Cuba mythology borders.
We deliver the another sloan quarter and remained encouraged by the performance of our business health of of the overall industry and our outlook for the future.
It is worth noting the Q2.2020 is the favorable comparative period due to the impact of the COVID-19.
The condemned recalls the widespread uncertainty the last year, which led to the clinic closures surprisingly the disruptions and shift in consumer demand from restaurant and foodservice 2 grocery stores.
The continually impacted Soho aspects of our companion, the animal and loss of our businesses.
Now, let's dive further into the details of the quarter.
Companion animal products led the way in terms of the species growth growing 36% operationally with large start growing 3% of operationally in the quarter.
Performance and companion animal was again, driven Barbera suicide portfolio Goodbye sogo compared to true and with significant contributions from the broader portfolio.
We also continue to see growth in our cooler mythology products of recruiter on side of the point as well as the and vaccines and diagnostics.
The burgers for your continued to perform exceptionally well posting revenue of $139 million representing growth of of more than 200% versus the comparable 2000.2030. In addition to the so we're keeping our other performance measures of goodwill such as clinic for the duration sure within furniture, the clinics and reordering Richard.
The.
The strength of of our entire companion animal person for portfolio was dividend again this quarter for a 50% operationally with meaningful growth in the full of heart and Revolution stronghold franchises. In addition to the imperative of French fries.
Having the board of the most innovative portfolio within the larger of extending therapeutic Ariel This was bullish on future growth and burst of the sites.
Global sales of our keeping the policy portfolio with $280 million in the quarter growing 22% of operational.
Side of 100 for 13 will be strong quarter going 42% of operationally and generating quarterly revenue of $100 million for the first time since launch.
Due to the sales for keeping a massage the products of $500.4 million and all of the remains unchanged. The sales will exceed $1 billion. This year.
Are the are nasty portfolio of head operational growth of 38% in queue too goodbye increases in the queue rule and instrument revenue as the business continues to recover from the impact of of the pandemic.
With our sustained investments and diagnostics the new technology, we are bringing for the market and the ability to leverage the breath of our medicines investment portfolio, we are well positioned to grow faster than the diagnostics market, which is expected to grow double digits and the outpaced the overall animal health market.
Lots of our growth in the quarter was driven by our cattle and swine businesses.
3% on swine grew 6% operationally despite the price reductions as part of our generic defense strategy and her input costs weighing on producer parts of ability in the U S.
Data suggest the foodservice in the restaurant industry has continued to recover in the second quarter, which is a crucial dynamic for demand of our premium products.
History was the only species the decline in the quarter, which flow of 4% of producers in the U S extended their use of lower price alternatives to our products the decline in poultry, partially offset the growth of cattle swine and fish products.
Now, let's discuss the revenue growth by certain of for the quarter.
<unk> revenue from the 22% with sales of preparing the animal products growing 34% and less of our product sales declining 8%.
Eurosport of the revenue exceeded $1 billion for the first time the company history.
For companion animal federal ownership and for spending trends remain robust.
Revenue increased double digit from the quarter and patient visits and spend per visit for up as well.
While reflect some of the trends the moderate or view is the will remain above free COVID-19 levels.
The meaningful portion of pet acquisition, which occurred during the pandemic, whereby millennials and Josie.
The confuses the solid foundation of of younger Pip ownership, who are willing to spend this will function of only more on all aspects of February of prior generations and will be of key growth driver for companion animal medicine vaccines and diagnostics moving forward.
Comparing the animal person for my portfolio was the largest contributor to companion animal growth in the us where in 59% in the quarter.
David mythology products vaccines and diagnostics also contributed to growth.
Some barrack of trio had an incredibly strong quarter in the us with sales of $120 million generating the highest revenue by a single product in the U S for Q2.
The Super of the franchise generated sales of 100 of $53 million growing 96% and remained the number 2 brand in the US fleet took in hardware market.
Cuba mythology sales were $197 million for the quarter going 23% with significant growth for outgrown the total points.
So as gnostic sales increased 22 percentage of the quarter with broken instruments rapid test for the pure consumables and reference led revenue.
Gross less stock sales, so 8% of the quarter driven by the declines in cattle and poultry with swine essentially flat for the quarter.
Q to cuddle sales with negatively impacted by the promotional program in the first quarter of this year, which pull forward the portion of second quarter sales.
In addition price reductions as part of our generic defense strategy and higher input costs weighing on beef and dairy and markets presented challenges to a couple of business this quarter.
Poultry decline in the quarter as producers expenses use of lower cost alternatives to our premium products as a result of higher feet, Paul and labor wages and smaller class sizes, reducing disease pressure.
We also of fate generic competition for Zanex or alternative to antibiotics and medicated food additives.
To summarize R. U S operations deliver the another strong quarter, but the are innovative and robust companion animal portfolio. The.
The end market dynamics for companion of animal remain the extremely healthy we fed on the ship, but spending trends driving in the environment conducive to sustainable future growth.
Which is the choices of more than offset the near term weaknesses.
Who is part of our business.
Now turning to our international segment.
Revenue in our International segment also grew 22% of operational in the quarter of comparing the animal revenue growing 41% and lost stock revenue growing 10% of operational.
The trends cooling strength and our international companion animal business are very similar to those in the us.
The interesting medical physician reach and standard of care by pet owners, coupled with significant investments in advertising and promotion to support new product launches and key brands true of growth of across Orcher suicides vaccine diagnostics anti dermatology portfolios.
Diagnostics for 106% operational in the quarter will consumables in instrument revenue each exceeding 100% of operational group.
The gorilla are monoclonal antibody for deviation of all of a pain in dogs launched in the <unk> in the second quarter.
Feedback from the early experience trials in queue, Juan was encouraging and second quarter sales exceeded our expectations further supporting optimism on the long term blockbuster potential of the product as well as monoclonal antibodies as the platform for future growth.
Our free line monoclonal antibody for alleviation of already paying Valencia begin early experienced programs in the second quarter with an ear launched following in Q3.
As previously mentioned or the pain in cash is the significant unmet need an animal health and we're excited to provide pet owners with the novel product in the space. The has previously lack of innovation.
Meanwhile.
While our international livestock business headed second concerned.
With growth across all species.
Net by strong operational growth in kettle of insulin.
Kind of growth in the quarter was driven by marketing campaigns key account penetration and favorable export market conditions in Brazil, and several other emerging markets.
Revenue growth and slides is largely attributed to China, which will be 38% operational the fees for growth and swine remained consistent with previous quarters has lost key accounts increase their use of our vaccines and other products as the continues to expand production of the market shifts from smaller farms larger scale of modern.
Operations.
Are efficient portfolio of continues to perform very well growing 25% of operational.
Both of those driven by strong performance of off of floods and chili vaccine volume of Norway, and the 2020 acquisition of the Fisher group.
For a market for prospective lens, all major markets with double digit from the second quarter for this.
And which declined slightly and Q2.
China, and Brazil had strong quarters growing 30% of 40% respectively on an operational basis.
Wilson companion animal across the emerging markets remains the key driver of our international business and in addition to the growth in China, and Brazil, or other emerging markets companion animal business grew 68% operational.
Overall, an international segment delivered strong results demonstrating the importance of our diversity of your call species in geography.
For the lifestyle business continues to perform well and increasing per acquisitions and picture of spending are extremely encouraging trends for long term growth and companion animal.
Now moving on to the rest of the piano.
Adjusted gross margins of 70 is essentially flat on the reported basis compared to the the prior year as favorable product mix and price were offset by higher manufacturing costs of free.
Adjusted operating expenses increased 23% operationally, resulting from increased compensation related costs advertising and promotion expense and free.
The is just the the effective tax rate for the quarter was 20%. The decrease of 230 basis points driven by the favorable impact of of jurisdictional mix of earnings Laura guilty tax and an increase in favorable discrete items compared to the prior year's comparable quarter.
But just the net income and adjusted the dilute EPS grew 28% of operational and for the quarter, primarily driven by revenue growth.
We remain in the very strong the creative physician and continued our share buyback program repurchasing approximately $165 million worth of shares in the quarter.
The strength of of balance sheet and substantial free cash flow generation allows us to make significant investments for future growth, while still returning excess cash the shareholders.
Before I review of updated guidance I would like to reiterate the point that has been discussed on prior earnings calls, which is that we expect growth to moderate in the second half of the year as a result of varying comparative periods, where pent up demand created by COVID-19 in the first half of 2020 work its way through the system and the second half of the year.
In addition to the expected increase generic competition for Jackson of <unk>.
Dusting for the variability in the comparative period due to the pandemic are facing of top line growth would be more normalized and consistent quarter to quarter throughout this year.
Now moving onto our updated guidance of 2021, which of our raising and therein. As a result of our second quarter performance strength of our product portfolio and favorable market dynamics, which we expect to continue.
Please note that our guidance reflects foreign exchange rates as of mid July.
For revenue, we're raising of narrowing our guidance range with projected revenue now between 7625, and $7.7 billion in operational revenue growth between 12.5% and 13.5% for the for Ya versus the 10.5%.
5% in our May guidance.
Adjusted SG&A expense for the year are expected to be between 1.87 and $191 billion versus 182, and 1 for $87 billion in our prior guidance.
The increased spanned represents additional advertising and promotion investments the security.
Significant portion of which will occur in the third quarter as well as compensation related costs due to the company performance.
Adjusted the income is now expected to be in the range of of $2 once the 5 and $2.175 billion.
Representing operational growth of 13% to 15% for both of our part of guidance of 12% of 14%.
Adjusted diluted EPS is now expect it to be in the range of $4.$40.724.65.
And reported diluted EPS to be in the range of for the.
The $4.19.
Not the summarized before we move on to Q&A.
R. A strong performance in the first half of 2021 continues to underscore the value of our the diversity innovation and durable business model.
The again raised in narrow our full year of 2021 guidance and affect the grow faster than the market.
We continue to focus on long term sustainable growth by investing in our pipeline, including infrastructure for support current and future photos losses and remains very positive in our outlook for sustainable growth beyond this year.
Now hand things over to the operator to open the line for your questions of.
Right on the grill.
And what to get him out of style.
If you would like to ask the question as a reminder to ask that you limit yourself to 1 question.
We'll take our first question from Michael Ruskin with Bank of America.
Thanks for taking the question of those and congrats on another strong quarter.
I want to start.
Some part of the trio, just a really breakout quarter pounder $39 million.
I mean by our projections something in the in the for the 5 under the range.
The amount of the thanks for for the rest of the year of so just wanted to get a better sense of where you seem an incremental growth coming from.
The total opposite of of took down in regular some part of it in the us year over year from just wondering if you could come out of it but again on on cannibalization to some of your expectations of that you move forward.
And then my second question will be on the operating leverage.
Some of the talk about in the past the government's John notable step of sequentially and SG&A coming in some of the above my estimate the.
You mentioned a lot of advertising spend a lot of competition related expenses.
Give us a sense of.
How much the verses going forward the thousand is going to play the role in the in the operating leverage in the second half of the year.
The comps I want to get a better sense of of what goes into that 490 million in the policy.
About that.
Great. Thanks, Mike I think the first question and I'll, let let me take the second question on the leverage accounts in Paradise and Purgatory of it did have a phenomenal Carter overall is that what we mentioned we had 50% growth of parasiticide.
But as you look at the quarter for trio of $139 million.
It was incredibly strong and I would say trail is and has been outpacing our expectations in fact, the compared to the franchise and Q2 was the second largest in the fleet Tech Heartworm space. So we're very excited.
We expect to continue to see the product row.
End of the market itself is you know.
Over $5 billion. So we remained super excited we're doing well both of our penetration of clinics as well and Reorders. How we see strong momentum that we think will continue into the second half of the year. So I'll, let let me take your second question Yeah in terms of SG&A Indeed the.
Step up that you see in terms of the trend.
There is really losses driven.
By R&D invest.
So the largely what's what's driving in in terms of compensation for their courses of really more of variable compensation.
Areas that are really in line with the performance of the company.
There as well.
And when you're looking for our next question from John Block, what's the phone.
Great sales guys the morning.
Presumably all sorts of of monoclonal and I know it's early.
How are you seeing highbrow of being used in the international practices in other words of the market expansion of the taking share from.
Other solutions are cannibalization of the room at all any color you have there would be helpful.
Of the shift gears of March it's always shopping to move around and is there anything or structural going on in the U S market.
And we're going to generic competition and maybe on that last point in traction playing out you mentioned and it seems like maybe you must of had to date for you.
Your assumptions still unchanged thanks, guys.
Sure. Thanks, John added to hear from you I will take the first question outlet.
Let me take the second question on livestock, we have been very excited at the uptick in Nebraska.
Of what we're seeing in your question about how is it really being used we've seen really strong efficacy of the product the.
Feedback we've gotten net too early experience in our first quarter of sales is just really quick efficacy. So noticing differences pretty quick at.
It's improving quality of life better social ability. So we really think more and more of that sort of looking at this is the first line therapy. We do think that there are significant opportunities as pileup relative grow the category.
The dog categories, you've talked about before currently is $400 million, but we believe by bringing the type of innovation to the market. So part of on globally by bringing decided innovation from the safety and efficacy profile. We think we have the ability to potentially double of that market. If you look at how many dogs. There are how many have OA and how many are treated so.
We looked at the opportunity for this market and the few ways certainly as I talked about getting more animal on getting more days on treatments and better compliance and then certainly with price of this product is price at a premium to those are already on the market. So when did you want to take the second question of AIPAC, Yeah sure for in terms of livestock, we don't see of structural change here.
In terms of your question and the performance of we're seeing is right in line with our expectations, let's start group of 3% on the quarter and as we've said plus of his tend to grow somewhere around the 4% range in the past, where we took the low single digits. This year and really the global growth in that area of driven by an international markets, particularly when you think about emerging markets of China.
And Brazil, et cetera, and the us with the generic competition.
<unk> for Jackson, the expected to see.
From headwind, there and it's really playing out in line with our expectations..1 more point I'll make is if you recall in Q1, we did have some promotions again in line with our generic defense strategy that really accelerated some of our revenue for Q1 from Q2. So that's playing out of a little bit in terms of what you've seen in the last like figures for the us what we expect to see further the.
Declines in terms of livestock for the remainder of the year and all of that for factored into the guidance that rebates today as well.
And we will take our next question from the least channel of cancer.
Hi, Thanks for taking my question here, John Kerry Anne how adorable, you think the increase in that visit.
Spend for Pat will be over the longer term. Thank you.
Thanks for it's great to hear from you and we're very confident in the day or ability of the companion animal trends that you've seen throughout 2020 and 2021.
So as you look in the quarter, we saw overall clinic revenues up 14% and that was equally split the.
Between the vet visits and spend per visit and our confidence in the.
From will trends really has to do the few things 1 there are more past we've talked about that for a number of of quarters. The other thing is it's an increase in the standard of care of the expectations of pet owners greater use of across the portfolio greater use of diagnostics.
More people from noticing more about their pets, but the other real important trend is going to continue to play out of the cruise adopting a lot more of these past.
A lot of millennials engender, the and they kind of spend more on their pet they're very engaged in their care. So we see these as durable trend that will continue and will remain a bit gross driver for the company of over the coming years.
And we will take our next question from John Cranker with for you Blair.
Hi, Thanks, very much either gross margin question I realize the monoclonal are sort of the new class for you guys as as the lengths in Liberal of Ram do you expect the gross margin on those products to be better or worse than what you see across the traditional product portfolio.
Yes, John look we certainly given the safety and efficacy profile of these products, we expect them to the price of significant premium to.
The existing therapies, including on <unk>, So I would say it would be above.
Sort of of our ridge gross margin that vehicle for portfolio.
Great. Thanks, a lot of it.
Hi, John.
And the food, we'll take our next question is from <unk>.
I'm, sorry can you try hand with credit Suisse.
Hi, Thanks for taking my question.
The highlighted the strength of the diagnostics Inc.
About some of the advantages and success that you've had the bundling strategies. The therapeutics and can you speak to what you're seeing in terms of competitiveness competitive placements for insurance you also called out the news that scan images platform and how has that been performing today and and how do you expect that the contribute to growth of the business day.
Alright. Thanks.
Thanks Katie.
As you look of diagnostic that was the very strong quarter with 38% operational growth.
The diagnostics the talked about remains of very attractive segment with double digit growth and it really is.
The core to the way that that practice operates again pets cannot tell.
Tell you exactly how they're feeling so we continue to see that being a really strong part of our continuum of care strategy, it's critical to the vet practice.
Credibly strong growth as you saw in the quarter of an international making significant placements very strong in the U S and we're focused on a few things there are certainly at the placement as we've talked about where we are seeing growth are stronger in the quarter and international than the U S. But also really driving consumable use and we think that remains a big opportunity for us versus competition.
Getting more considerate of will use in the placements that we have and then really adding onto that the innovation. So.
Plus it has done better than our expectations. We continue to see very strong growth there right now the indication for a day of Afghan images as an equal and that the large market is about $500 million growing at 7% to 8%. So we see really strong growth area of acres anything you'd at least over the 1.
That's true.
And for you, we'll take our next question from Dayton West of Berkeley.
<unk>.
Hi, Thank you for taking the question I'm Gonna Guy should continue on that concept and can you that was just astronauts Katie can you help us conceptualize the size of the non therapeutic revenue for Zoetis on the go forward basis, and whether or not we should see it as a regular contributors medium means of driving therapeutic revenue and I'm going across the categories.
Diagnostics insurance and breaks genomics et cetera, and then just a quick clarification question the the <unk>.
John blocks question on the doubling of the pain market was that just in dogs, and then cash plus.
Plus beyond that or was that $800 million of the doubling of square and a million dollars just for dog and cat. Thank you.
I'll start and free of Christian wants to add anything in terms of non therapeutic if you look at diagnostics for example, where rissole, 38% growth. This this quarters of roughly $99 million of revenue on the quarter on the base of were reported for the for the year. So is in relative terms, if not the largest proportion of our of our revenue streams.
Certainly, but we're very very much excited about the the potential for the future and the very fast growing market for the diagnostics with the this recipe grow faster than the overall animal health the space for us and really 1 more point that Omega overall, we took the diagnostics is kristen covered earlier because of the impact of the continuum of care.
We think overall.
And use of diagnostics as we look to medicalization the across across the pet will have a positive effect on the overall of therapeutics and the long haul. We think that that's also an exciting opportunity for the long term for sure and I can take your second question with regards to the cat market, Yes, we think that when the incremental it as of.
The little hard to size the cat market today of there's really not much of an OA pain market in the US there is on the international products that are approved by as we talked about doubling the dog from 400 to 800 million.
Kenneth the little harder type of the cat market, maybe for 100, we think you can double of that as well. So I think that could be of $200 million market, which would make the OA category for us across dogs and cats potentially of $1 billion market that we can plan. So we think of very exciting space for us.
Okay influencing for our next question from probably the only thing shot with Barclays ear items now okay.
Good morning, and thanks for the questions just couple of for me for key on the part of Society. Marquette do you have a sense of relative size of land next garden the brand Cola in the quieter and the for trio growth came out of the cost of competent as our income market expansion on the same point you recently got a name of the expansion for some biker.
Could you also just described bulb. Thank us for the implications for it constantly on on the Diamond side.
David to what led to of 1% of any guide change on the on the top of an increase in his gender and windows, including the the X men in terms of being too. Thanks.
Sure. Thanks for that I will take the App for.
First question and I will let me take the second line as.
As we look I don't I can't get into what our competitors are products of the sales are we remain quite excited for some characters doing we did get the additional labor claim.
That was expected that was included in the guidance that we had in the sense of where are we getting some of those sales from it is and and so we are both growing the market I think more people are moving back into.
The prescribed products versus some of the over the counter but we're also seeing that we are taking share from any of our competitors as well. So that's an exciting opportunity of across both dimensions.
If you want to take it the other question.
1 thing I would add in terms of first of the sides minutes of 5 billion dollar market.
That's going around 5% and we're gaming share in this marketplace, we do think that with the triple combo is.
It's improving compliance with respect of heart worm et cetera, and so that will have the opportunity to continue to expand to extend the the market as well. So we're very pleased with the performance. The cross offers his portfolio and the sure that we're getting and we will continue to invest behind.
Behind the.
Of the spotted from this loan portfolio as well and you want to take the increase in guidance.
Yes, certainly.
Certainly and when you look at our guidance.
Compared to where we started in the year and given the overall market positive market dynamics that we see are for.
Folios for forming very well Chris.
Kristen covered some of the the trend around the vet visits and so on all of those are contributing towards optimism and you are seeing the year to the performance of it was delivered and in fact, we've taken our guidance in terms of top line operational growth of from where we started in the year of 911% now at 12 and after 13 of 5 so for 3 points above where we start.
The year so of rupees with how we started the year I think if you look at.
Overall perspective, certainly the first half of the second half of the year. If you look at the purely topline daily roughly in line for.
Pretty consistent.
Sort of phrasing of across the year, the growth, which will moderate based on last year largely not really.
Matter of of how this year is executing for US we're in a very positive market dynamic with very strong performance of course of our portfolio last year given the pandemic there is a bit of variability across of the year. There was disruption in the first half of the year, given COVID-19, which created more demand that got pent up and caught up in the back half of the year of so that's going to create a dynamic.
In terms of what the.
The visa looked licenses of groceries for sectors of the second half, we're very pleased with where you are and we're going to continue to invest behind our key portfolios.
Portfolios and brands.
And for you we'll take our next question from Chris shot with J P. Morgan.
Great. Thanks, so much for the questions I just want the purpose of a little bit more on U S livestock.
Can you talk a little bit again about the <unk> dynamics cause it seems like you are going up against the fairly easy comp. The this was still down about 8%. So I was sort of get a sense of like as we think about the rates of decline you expect the in the business from the second half of the year just help us conceptualize what type of of erosion, you're thinking about as we go up against which seems like some tougher comps for those quarters and.
Of the mixture of longer term perspective can you talk a little bit through but how you're thinking about recovery for U S. Livestock because of the thing about both poultry and cattle as as we get past some of these kind of more challenging near term dynamics and your sense of what the longer term business. Thanks, so much.
Thanks credit alternative.
More of the strategic drivers and I'll, let let me get into some of the specifics here.
The last I'd really have performed as we expected.
And as we talked about going into the year with the low Dragon. We did expect the decline in general as we talked about for at last year's that's generally 20% to 40% over 2 to 3 years and as we said we thought that would be factor as you look at the quarter, we did the of 19% decline.
Overall interaction specifically.
That is 1 of the key factors in the U S and when you've mentioned earlier I think continue but if you look at the broader of livestock historically, it's a low to mid single digit grower certainly as you saw in 2019 with ASF in China in 2020 with Covid, it's been lower than what is historically seen we do believe that the.
The day it overall the whole trend back.
2 of the market growth in the mid simple they just call it the around the 4% range, maybe 3 to 5.
And then we think the west will be in line with that.
It could be slightly lower of in the next few years of you see this year and really the strategic driver of that is that we had the number of the largest number of products hitting lots of exclusivity. If you look at our guidance. That's why it is baked in so it wasn't distract and we also have infiltrated youre just referencing.
Had an accident and BMD as well, but again the that good growth in some of these other species as well as you look at poultry, we're really excited at the growth of our vector vaccines of the $300 million market growing 13%. We've already launched 2 of them new capital of IBD and that will be of growing portfolio of for us, but I'll. Let you know when you get into some of the more specific numbers, but I do.
Inc. As you look at livestock, just more strategically on the higher level I think it's going to be a lower part of the companion animal, but we do think it goes back of historical levels Whitney and if you want it built on that yeah look I mean, if you look at last stock across the world, we're putting consumption population growth and income levels rising et cetera, we expect them to continue to drive growth and livestock.
For the long term.
We delivered 3% on the year as we said is expected of as was covered in the prior earnings call. We expected the declines in the us, particularly given the generic entry for for Jackson now the first quarter the benefit of bit from 2 things 1 of those a little bit of the delay in terms of the entry of generic for Jackson, but also we rented promotion in the first quarter.
The acceleration revenue for Q1 taken it out of the queue too. So if you take those into consideration which are exactly in line with our defense strategy lifestyle really is performing exactly as we expected.
Given that the.
The distribution of generic competition as we expected just begin really into the lead first quarter into the second quarter. We expect of those declines to continue and again the right in line with our expectations here.
And we will take our next question from the scanner with Kelly.
Thank you a local paper in Nebraska reported last week that library is being manufactured at the Lincoln plant. If that is correct. Then is the product ultimately destined for the U S and.
The U S regulatory process. The evolves can you confirm that it is still the case that no new clinical data is required. Thank you.
Sure we.
We met on the I mentioned earlier, we do believe we will see approval in the U S for both of of Rella NFL NCS.
The 2022 with lowbrow, the most likely in the second half.
We have long term strategies.
Obviously multiple sites I don't think the U S will be manufactured out of labella at launch we certainly are looking at potentially adding.
Adding face just given the strength of as I mentioned earlier of that product. So we have been having ongoing the conversations of regulatory authorities and remain on track for the guidance. The previously provided which is approval for both of those products that with Valencia likely earlier in the year and revolved layer, but you should not probably expect the producing out of Lincoln, Nebraska at months from about.
Look given our global footprint and the.
<unk> presence.
Should not be the anything into the location of manufacturing and.
Of where the products are the best in too.
Particular will continue to leverage both of our own for point as well as third party for non infection.
And so I wouldn't I wouldn't join the conclusion from that.
Can we will take our next question from Elliott Wilga with Raymond James.
Hi, guys. This is actually Micropower, Larry Dillon and for for Elliott. Thanks for taking my question.
So I believe you said in the past the trio.
About of 90% of too.
Top corporate accounts, just wondering if you could provide the update go on penetration across all the targeted accounts.
And then in relation to the GTC campaign.
No you said in your prepared remarks that it remains beneficial, but just wondering if you could get the updated timeline.
How long you could see of continuing and then also how you see.
Incremental spend really driving on the lies here. Thank you.
Sure. Thanks Micheal.
We continue to be very we are.
Or surpassed all of the clinic penetration of that we expected for trio. The we're quite pleased with that in right now where I'm a little more focused out of the order right. As I mentioned, we think that's part of transcripts now I think our penetration is where we would expect it and is very broad across the U S for trio and working in a really from the standard those reorders, which we now have of 80% in continuing.
To grow the overall reorder rates direct to consumer advertising is critical in this category of it is 5 billion. It is the category that consumers really do go in and ask for brand we.
We do obviously track of Roy.
As you've seen in his wedding I mentioned earlier, we will continue to invest behind the brand we've seen incredibly strong Roy in doing so and that is why you're seeing a step up that.
As we talked about earlier it has outpaced our expectations I think that has everything to do with the innovative nature of the product, but it also has to do with the <unk>.
Investment, we put behind that and direct to consumer average and.
And investing with our field for us and we will continue to do that you should expect this year and next year, certainly we have a window of opportunity with no competition in the U S and we will leverage that opportunity.
We still don't know exactly when we will see competition at this point, we don't expect any for the second half of 2022 of the earliest as we mentioned by the as long as we do not have competition, we will invest aggressively behind the brand and even when we do we will do it as well because we've seen the very strong Roy in doing that.
For some kind of.
Question from the same time city.
Hi, Good morning could you comment on capital allocation chili.
Continuing of financial policy going for it.
<unk> thanks for the.
Expansion.
Yeah, both of 'em acquisition in addition to the interviewing but thank you.
Yeah sure of so in terms of the capital allocation of you should expect consistency in terms of how we.
And it's capital of allocation with the focus first and foremost an internal investments the of opportunities in terms of R&D investing behind our brands on advertising promotion perspective, capex to support our growing pipeline, including monoclonal antibodies et cetera. That's really offers priority of course will take advantage of any opportunities from of business development perspective.
For MMA that helps to accelerate of.
And for various markets in the areas as well so that really follows on in terms of investments and then as we have.
Free cash flow generation versus non free cash flow rash and we'll look to return.
Cash flow our shareholders, we of interest on dividends as you've seen tip.
Typically faster than our revenue and.
The initiated our share vulgar and which we will continue.
Remains consistent I would say with the first.
And then I am director on at this comment on that the geographic center. So look up took advantage of rocks as we're excited to be bringing them once we get through the.
The processor for the next 6 months and close the transaction, which side of the brain.
The jurors into the Zoetis family, Australia's our fifth largest market.
I believe this is really out of our core it goes into.
The increase our presence in the therapeutic area.
New products as well so we're very excited about that opportunity of what it goes for us and we will continue to look for Bolton opportunities to.
Bring on both of course, well as the other areas of the business.
Whether it's diagnostics, but what have you as well.
Kind of instant conclusion question and answer session I will now turn the copay back over to Christian credit for any additional are closing remarks.
Great. Thank you everybody for your questions today and for your continued interest in Zoetis.
We look forward to keeping the updated our business throughout the remainder of the year for continuing to deliver on our results and innovations I think you and our customers expense. So thanks, so much for joining us today.
This does conclude today's program. Thank you for your participation disconnected anytime well have a wonderful day.
[music].
Uh-huh.